1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
December 2025 in “Clinical and Translational Science” EGFR inhibitors in breast cancer treatment can cause serious skin issues affecting patient quality of life.
December 2024 in “Frontiers in Genetics” EGFR and mTOR inhibitors may help manage Olmsted syndrome symptoms.
EGFR helps protect hair follicles from damage and scarring.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking EGFR can lead to hair loss due to inflammation and stem cell damage.
January 2022 in “Dermatology Review” EGFR inhibitors can cause unusual localized hair growth.
October 2018 in “Oncology Times” Hair is important for aging and cancer treatment, affecting emotions, culture, and health.
September 2014 in “Aktuelle Dermatologie” The symposium concluded that environmental factors significantly contribute to skin aging.
March 2009 in “Dermatology Online Journal” Manipulating EGFR signaling may help treat hair loss and promote hair growth.
September 1998 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Intermittent isotretinoin can cause various skin, hair, and nail changes.
November 2024 in “EMBO Molecular Medicine” JAK inhibitors may reverse early hair loss, but prolonged inflammation can cause permanent hair loss.
April 2016 in “Journal of Investigative Dermatology” Decreasing MIG6 can increase the movement and invasiveness of MEK-inhibited mutant NRAS melanoma, particularly when stimulated by EGF.
August 2020 in “SKIN The Journal of Cutaneous Medicine” Cetuximab can cause skin cysts after acne-like eruptions.
September 2016 in “Journal of dermatological science” Collagen XVII is crucial for skin cell growth and nail health.
4 citations
,
March 2007 in “British Journal of Dermatology” Gefitinib therapy can cause unusual hair growth on the nose.
3 citations
,
September 2016 in “Dermatologic Therapy” Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
15 citations
,
January 2014 in “Medicinal chemistry” Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.
November 2010 in “International Journal of Dermatology and Venereology” EGFR inhibitors can cause skin issues, and managing these is important for treatment success.
12 citations
,
January 2014 in “Journal of international medical research” Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.
1 citations
,
October 2022 in “Дерматовенерология Косметология” EGFR inhibitors for lung cancer can cause severe skin issues.
Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.
14 citations
,
June 2012 in “Stem Cells” TACE/ADAM17 is essential for maintaining healthy hair and hair follicle stem cells.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Targeted cancer therapies can cause skin side effects, but activating SOS in the skin may help reduce them.
94 citations
,
July 2003 in “Journal of biological chemistry/The Journal of biological chemistry” EGF controls hair growth by regulating hair follicles' growth phases.
83 citations
,
October 2016 in “Stem Cells and Development” Epidermal growth factor helps hair stem cells grow by activating specific cell pathways.
12 citations
,
February 2010 in “Journal of The American Academy of Dermatology” A cancer drug caused unusual hair growth on a 100-year-old man's scalp and eyelashes.
September 2021 in “Assay and drug development technologies” Drug repurposing shows promise for treating many medical conditions.
25 citations
,
January 2017 in “Steroids” Allopregnanolone increases growth and changes gene activity in human brain cancer cells.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.